Sandoz is expanding its presence in Slovenia. The Basel-based generics giant has launched the construction of a new biosimilars production centre in Brnik at a cost of $440 million (CHF349 million). +Get the most important news from Switzerland in your inbox The announcement brings current and planned investments in the small Alpine country to more than $1.1 billion by 2029, according to a press release issued on Tuesday by the specialist in generic and biosimilar treatments. These include a new biosimilars production centre in Lendava and a development centre in the capital, Ljubljana. Sandoz intends to take advantage of an “unprecedented market opportunity”, with patent expiries expected to reach $222 billion over the next ten years. The Group believes it is the leading foreign direct investor in the European country. Translated from German by DeepL/jdp How we work We select the most relevant news for an international audience and use automatic translation tools to translate them …